Turning the Tide on ATTR-CM: The Science and Evidence

Join guest Dana Miller, Advanced HF Nurse Practitioner, to discuss the science and evidence to turn the tide on ATTR. Dana provides an overview of recent clinical trials and how an ATTR-CM diagnosis impacts rate of hospitalization, mortality and quality of life. Dana shares resources and recommendations to continue to learn more about the ever-evolving ATTR-CM treatment and management strategies.

Related PCNA Resources:

The Role of Artificial Intelligence in Cardiovascular Care: ATTR Case Study (CE Course) 

Heart Failure and ATTR-CM: A Guide for Health Care Professionals 

Hereditary Amyloidosis: What you need to know fact sheet 

Related Episode Resources:

CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis

Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance

Changing Patterns of Diagnosis and Survival in Transthyretin Cardiac Amyloidosis: A Multicenter Cohort Study

Outcomes in patients with cardiac amyloidosis undergoing catheter ablation for atrial arrhythmias

Amyloidosis Research Consortium

Heart Failure Society of America (HFSA)

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.